The content on this site is intended for healthcare professionals only
Dr Ibrahim Aldoss speaks to ecancer about the outcomes of the pivotal augment-101 phase 2 study, focusing on the effectiveness and safety of revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukaemia.
Revumenib, an inhibitor targeting menin-KMT2A interactions, exhibited promising efficacy and safety during a preliminary phase 1 study involving R/R KMT2Ar and nucleophosmin 1-mutated (NPM1m) acute leukaemias.
This phase 2 study aimed to present key findings regarding the efficacy and safety of revumenib in the treatment of patients with R/R KMT2Ar acute leukaemia.
The results indicated that revumenib yielded clinically significant outcomes in a heavily treated KMT2Ar population, showcasing a high overall response rate, minimal residual disease negativity, and subsequent successful haematopoietic stem cell transplant.
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Ide-cell enhances health-related quality of life for refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Hodgkin’s and non-Hodgkin’s lymphomas (NHL)
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment
